Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Regeneron Pharmaceuticals Q1 2024 Adj EPS $9.55 Misses $10.10 Estimate, Sales $3.145B Miss $3.221B Estimate

Author: Benzinga Newsdesk | May 02, 2024 06:31am
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.55 per share which missed the analyst consensus estimate of $10.10 by 5.45 percent. This is a 5.35 percent decrease over earnings of $10.09 per share from the same period last year. The company reported quarterly sales of $3.145 billion which missed the analyst consensus estimate of $3.221 billion by 2.37 percent. This is a 0.54 percent decrease over sales of $3.162 billion the same period last year.

Posted In: REGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist